Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age

Bone Marrow Transplantation

Volumn 32, Issue 12, 2003, Pages 1135-1143

  Reece, D E ^a   Bredeson, C ^b   Perez W S ^b   Jagannath, S ^c   Zhang, M J ^b   Ballen, K K ^d   Elfenbein, G J ^e   Freytes, C O ^f   Gale, R P ^g   Gertz, M A ^h   Gibson, J ⁱ   Giralt, S A ^j   Keating, A ^a   Kyle, R A ^h   Maharaj, D ^k   Marcellus, D ^l   McCarthy, P L ^m   Milone, G A ⁿ   Nimer, S D ^o   Pavlovsky, S ⁿ   To, L B ^p   Weisdorf, D J ^q   Wiernik, P H ^r   Wingard, J R ^s   Vesole, D H ^b   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c ST VINCENT S HOSPITAL MANHATTAN   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e ROGER WILLIAMS MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g Center for Advanced Studies in Leukemia   (United States)

^h MAYO CLINIC   (United States)

ⁱ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k Bethesda Health City   (United States)

^l JURAVINSKI CANCER CENTRE   (Canada)

^m ROSWELL PARK CANCER INSTITUTE   (United States)

ⁿ Fundacion para Combatir La Leucemia   (Argentina)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p HANSON INSTITUTE   (Australia)

^q UNIVERSITY OF MINNESOTA   (United States)

^r NEW YORK MEDICAL COLLEGE   (United States)

^s UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Autologous transplantation; Multiple myeloma; Older patients

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; NITROSOUREA; PREDNISONE; THIOTEPA; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; GROUPS BY AGE; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NORTH AMERICA; OSTEOLYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REGISTRIES; RETROSPECTIVE STUDIES; SOUTH AMERICA; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0346496578     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704288     Document Type: Article

References (24)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
2. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
3. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high dose therapy with autologous stem cell transplant support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
4. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-3085.
5. Leger CS, Bredeson C, Kewarns B et al. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000; 6: 204-210.
6. De la Rubia J, Sadverdra S, Sauz GF et al. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 21-25.
7. Palumbo A, Triolo S, Argentino C et al. Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patient's blood. Blood 1999; 94: 1248-1253.
8. Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51-54.
9. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600-607.
10. Sirohi B, Powles R, Treleaven J et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533-539.
11. Dumontet C, Ketterer N, Espinouse D et al. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell vein fusion for multiple myeloma. Bone Marrow Transplant 1998; 21: 1037-1041.
12. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
13. Gooley A, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
14. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. Springer-Verlag: New York, NY, 1997.
15. Andersen PK, Klein JP, Zhang MH. Testing for center effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med 1999; 18: 1489-1500.
16. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838-847.
17. 2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood 2002; 99: 731-735.
18. Bjorkstrand B, Svensson G, Goldschmidt H et al. Autotransplants in multiple myeloma: a registry from the European Group for Blood and Marrow Transplantation (EBMT). Blood 1999; 94 (Suppl 1): 714a (abstract 3154).
19. Cunningham D, Powles R, Malpas J et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1999; 102: 495-502.
20. Berenson JR, Crowley JJ, Grogan TM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163-3168.
21. Alexanian R, Weber D, Giralt S et al. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002; 13: 1116-1119.
22. Rufffini PA, Kwak LW. Immunotherapy of multiple myeloma. Sem Hematol 2001; 38: 260-267.
23. Hideshima T, Chuhan D, Podar K et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28: 607-612.
24. Maloney DG, Sahebi F, Stockerl-Goldstein KE et al. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Presentation at the American Society of Hematology 43rd Annual Meeting and Exposition. Blood 2001; 98 (Part 1 of 2) 434a-435a (abstract 1822).